Section 410 ILCS 416/25 - Reimbursement requirements; notice(a) A reimbursement under the program at a trial site that conducts clinical trials must: (1) be reviewed and approved by the institutional review board associated with the clinical trial for which the reimbursement is provided; and(2) comply with applicable federal and State laws.(b) The independent third-party organization operating the program is not required to obtain approval from an institutional review board with respect to the financial eligibility of a subject who is medically eligible for a clinical trial.(c) The independent third-party organization operating the program shall provide written notice to a subject on: (1) the nature, availability, and scope of the ancillary financial support under the program; and(2) the program's general guidelines on financial eligibility.Amended by P.A. 103-0227,§ 5, eff. 6/30/2023.Added by P.A. 101-0619,§ 25, eff. 12/20/2019.